1. Home
  2. HFRO vs ANNX Comparison

HFRO vs ANNX Comparison

Compare HFRO & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Highland Opportunities and Income Fund of Beneficial Interest

HFRO

Highland Opportunities and Income Fund of Beneficial Interest

HOLD

Current Price

$6.04

Market Cap

362.0M

Sector

Finance

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$4.06

Market Cap

334.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HFRO
ANNX
Founded
2000
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
362.0M
334.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HFRO
ANNX
Price
$6.04
$4.06
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$16.60
AVG Volume (30 Days)
179.8K
3.1M
Earning Date
01-01-0001
11-10-2025
Dividend Yield
8.87%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.24
$1.29
52 Week High
$6.45
$5.66

Technical Indicators

Market Signals
Indicator
HFRO
ANNX
Relative Strength Index (RSI) 38.10 59.32
Support Level $5.90 $4.26
Resistance Level $6.30 $4.64
Average True Range (ATR) 0.20 0.37
MACD -0.01 0.07
Stochastic Oscillator 32.39 60.08

Price Performance

Historical Comparison
HFRO
ANNX

About HFRO Highland Opportunities and Income Fund of Beneficial Interest

Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: